Revenue (Tables)

12 Months Ended

Dec. 31, 2022

Revenue from Contract with Customer [Abstract]

Disaggregation of Revenue [Table Text Block]

The following table represents our revenues disaggregated by product line (in thousands) and our disaggregated product line revenue as a percentage of total revenue:

	Year ended December 31,
	2022				2021				2020
Product line	Revenue		% of Revenue		Revenue		% of Revenue		Revenue		% of Revenue
Infusion Consumables	$	566,617	25	%	$	555,189	42	%	$	473,740	37	%
Infusion Systems	351,080		15	%	352,321		27	%	359,691		28	%
IV Solutions	363,472		16	%	359,477		27	%	388,971		31	%
Critical Care	47,330		2	%	49,321		4	%	48,602		4	%
Infusion Systems-Smiths Medical	340,124		15	%	—		nm		—		nm
Vascular Access-Smiths Medical	326,765		14	%	—		nm		—		nm
Vital Care-Smiths Medical	284,609		13	%	—		nm		—		nm
Total Revenues	$	2,279,997	100	%	$	1,316,308	100	%	$	1,271,004	100	%

We report revenue on a "where sold" basis, which reflects the revenue within the country or region in which the ultimate sale is made to our external customer.    

The following table represents our revenues disaggregated by geography (in thousands):

	Year ended December 31,
Geography	2022		2021		2020
United States	$	1,460,069	$	941,809	$	910,627
Europe, the Middle East and Africa	367,411		147,488		132,763
APAC	257,208		85,692		79,610
Other Foreign	195,309		141,319		148,004
Total Revenues	$	2,279,997	$	1,316,308	$	1,271,004

Domestic sales accounted for 64%, 72% and 72% of total revenue in 2022, 2021 and 2020, respectively. International sales accounted for 36%, 28% and 28% of total revenue in 2022, 2021 and 2020, respectively.

Contract with Customer, Asset and Liability [Table Text Block]

Our contract balances (deferred revenue) are recorded in accrued liabilities and other long-term liabilities in our consolidated balance sheet (see Note 10: Accrued Liabilities and Other Long-term Liabilities). The following table presents the changes in our contract balances for the years ended December 31, 2022 and 2021, (in thousands):

	Contract Liabilities
Beginning balance, January 1, 2021	$	(6,430)
Equipment revenue recognized	10,048
Equipment revenue deferred due to implementation	(13,725)
Software revenue recognized	7,261
Software revenue deferred due to implementation	(4,615)
Ending balance, December 31, 2021	(7,461)
Fair value of acquired deferred revenue	(51,245)
Equipment revenue recognized	32,252
Equipment revenue deferred due to implementation	(20,332)
Software revenue recognized	16,277
Software revenue deferred due to implementation	(17,557)
Government grant deferred revenue	(3,729)
Government grant recognized	1,514
Other deferred revenue	(1,500)
Other deferred revenue recognized	5,915
Ending balance, December 31, 2022	$	(45,866)

Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction

As of December 31, 2022, revenue from remaining performance obligations is as follows:

	Recognition Timing
(in thousands)	<12 Months		> 12 Months
Equipment revenue	$	(15,144)	$	(982)
Software revenue	(8,277)		(1,026)
Government grant revenue	(1,422)		(12,797)
Other deferred revenue*	(4,784)		(1,434)
Total	$	(29,627)	$	(16,239)